Lusvertikimab
Based on 1 publication(s) in Google Scholar
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.41%
- CAS 番号: 2375835-91-7
- 分子量:145.64 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Lusvertikimab
More
生物活性
製品説明
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL7R |
体外実験
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IL-7R alpha/CD127 Protein (ECD, His Tag) can bind Lusvertikimab. The EC50 for this effect is 3.8 ng/mL. -
Flow Cytometry analysis of K562 cells labelling IL-7Ra/CD127 (red) with Lusvertikimab (anti-IL-7Ra/CD127) (HY-P99412). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 (S228P) kappa (HY-P99003). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 2375835-91-7
-
性状 Liquid
-
分子量 145.64 kDa
-
Color Colorless to light yellow
-
SMILES
[Lusvertikimab]
-
別名
OSE-127
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
Distinct functional heterogeneity of TP53 R175 mutations in platinum-resistant ovarian cancer: unveiling molecular mechanisms and therapeutic targets. [Abstract]2025 Nov 17;16(1):837. PMID: 41249788
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)